Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Dual Antithrombotic Therapy With Dabigatran
Author(s): Christopher P Cannon Added: 6 years ago
This interview with Christopher P. Cannon from Brigham and Women's Hospital, Boston, US discusses Dual Antithrombotic Therapy with Dabigatran After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation (REDUAL-PCI). Filmed by Radcliffe Cardiology on-site at ESC 2017. View more

Anticoagulation
Antithrombotic Therapy in Complex PCI Patients Under OAC
Author(s): Despoina-Rafailia Benetou , Panayotis K Vlachakis , Charalampos Varlamos , et al Added: 2 years ago

Anticoagulation

Intervention
Christopher P Cannon
Research Area(s) / Expertise:

MI/ACS

Unstable Angina & NSTEMI

 Job title: Professor
Dr Christopher Cannon is a Professor of Medicine at Harvard Medical School, and Senior Physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at… View more
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
Author(s): Johny Nicolas , Usman Baber , Roxana Mehran Added: 3 years ago
Seminal clinical trials conducted in the balloon angioplasty and bare metal stent era established the superiority of dual antiplatelet therapy (DAPT) as compared with aspirin monotherapy or anticoagulation with respect to the prevention of thrombotic events.1,2 Other studies found that the benefits of DAPT are durable for at least 1 year and extend to patients with acute coronary syndromes.3–5… View more

Anticoagulation
Author(s): Leo Buckley , Ahmed Aldemerdash Added: 3 years ago
Cardiovascular disease is the leading cause of death in the US.1,2 Although advances in the prevention and treatment of cardiovascular disease have contributed to a decline in mortality rates, this favorable trend has slowed over the past several years.3 Recently, however, a revival of cardiovascular drug development has introduced new treatment options to the market, with several promising… View more

Prevention & Chronic Conditions
Best Practices in Pharmacotherapy for Acute Coronary Syndromes
Author(s): Robert Barcelona Added: 1 year ago

Anticoagulation

MI/ACS
Antithrombotic Therapy in Chronic Total Occlusion Interventions
Author(s): Iosif Xenogiannis , Charalampos Varlamos , Despoina-Rafailia Benetou , et al Added: 2 years ago

Intervention
Antithrombotics in LM and Bifurcation PCI
Author(s): Charalampos Varlamos , Ioannis Lianos , Despoina-Rafailia Benetou , et al Added: 2 years ago

Intervention
Author(s): Donald E Cutlip Added: 3 years ago
Stent thrombosis has been recognized as a serious complication of coronary stent placement since the procedure was first reported in the 1980s.1 Subsequent aggressive peri-procedural anti-thrombotic strategies with inpatient transition to warfarin reduced the risk to about 3.5 % for subacute (30-day) stent thrombosis,2,3 a rate that would be unacceptable by current standards and did not account… View more

Prevention & Chronic Conditions

Intervention
Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention
Author(s): Dimitrios Alexopoulos , Charalampos Varlamos , Despoina-Rafailia Benetou Added: 3 years ago
Complex percutaneous coronary intervention (PCI) usually refers to procedures that include bifurcation with two stents implanted, the treatment of three or more lesions, the implantation of three or more stents, total stent length >60 mm, or a chronic total occlusion (CTO).1 However, as there is no universal definition, other features, such as left main (LM) or proximal left anterior… View more

Intervention